Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Apoptosis as an evolutionary battleground: pathogen pressure and the shaping of programmed cell death pathways.

Frontiers in cell and developmental biology·2026

Same author

Beyond bent-to-planar transformation: ICT and TICT dynamics in a novel disubstituted N,N'-dihydrophenazine.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy·2026

Same author

Cell surface GRP78 and the UPR pathway as novel promising therapeutic targets in cancer: an insight into the treatment of acute leukemia by using GRP78-CART cells.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026

Same author

Reactivation of <i>P53</i> Antiproliferative and Pro-Apoptotic Pathways by Resveratrol in Mutant <i>P53</i> Cancer Cell Lines.

International journal of molecular sciences·2026

Same author

Outpatient Delivery of Step-Up Doses to Rapidly Initiate Monthly Doses of Bispecific Antibodies in Multiple Myeloma.

European journal of haematology·2026

Same author

Concurrent L1 retrotransposition events promote reciprocal translocations in human tumorigenesis.

Science (New York, N.Y.)·2026

Search research articles

Related Experiment Video

Updated: May 26, 2026

Focus Formation: A Cell-based Assay to Determine the Oncogenic Potential of a Gene

Focus Formation: A Cell-based Assay to Determine the Oncogenic Potential of a Gene

Published on: December 31, 2014

MAGE-A3 expression is an adverse prognostic factor in diffuse large B-cell lymphoma.

Irma Olarte¹, Adolfo Martinez, Christian Ramos-Peñafiel

¹Laboratorio de Biología Molecular, Servicio de Hematología, Hospital General de México, México D.F., México.

Hematology (Amsterdam, Netherlands)

|December 21, 2011

Summary

MAGE-A3 expression indicates a poorer prognosis in diffuse large B-cell lymphoma (DLBCL). This biomarker is linked to advanced disease stages and shorter survival, highlighting its potential clinical significance in DLBCL patient outcomes.

More Related Videos

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker

Published on: September 15, 2023

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Published on: November 11, 2021

Related Experiment Videos

Last Updated: May 26, 2026

Focus Formation: A Cell-based Assay to Determine the Oncogenic Potential of a Gene

Focus Formation: A Cell-based Assay to Determine the Oncogenic Potential of a Gene

Published on: December 31, 2014

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker

Published on: September 15, 2023

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Published on: November 11, 2021

Area of Science:

Oncology
Molecular Biology

Background:

Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
Identifying prognostic markers is crucial for tailoring DLBCL treatment strategies.

Purpose of the Study:

To evaluate the prognostic value of MAGE-A3 expression in DLBCL patients.
To correlate MAGE-A3 expression with clinical parameters and patient outcomes.

Main Methods:

Quantitative real-time RT-polymerase chain reaction (PCR) was used to assess MAGE-A3 expression.
The study included 28 DLBCL patients.
Associations with disease stage, lactate dehydrogenase (LDH) levels, International Prognostic Index (IPI) score, treatment response, and overall survival were analyzed.

Main Results:

MAGE-A3 expression was significantly associated with advanced DLBCL stages (P < 0.05).
MAGE-A3-positive patients exhibited higher serum LDH levels and IPI scores (P = 0.025 and P = 0.004, respectively).
MAGE-A3 expression correlated with poor treatment response and significantly shorter overall survival (P < 0.001).

Conclusions:

MAGE-A3 expression serves as a significant indicator of poor prognosis in DLBCL.
These findings provide novel insights into the role of MAGE-A3 in DLBCL progression and outcomes.